ClinicalTrials.gg
CompletedNCT04172831RELIEFUpdated Aug 8, 2022Results posted

A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

A Phase 3 interventional study of TNX-102 SL and Placebo SL Tablet in Fibromyalgia, sponsored by Tonix Pharmaceuticals, Inc.. Completed at 39 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-08-08.

Sponsored by Tonix Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
503
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.

Enrollment
25th of 320
503 · median 72
Started
2019
with 15 others
Phase 3
55 of 369
2 open now
Registered
268th of 369
by date
Lead sponsor
8 of 369
Tonix Pharmaceuticals, Inc.

Among the 369 studies in Fibromyalgia with a site in United States, this one is the 25th largest by enrollment of the 320 interventional ones that give a count, is one of 16 that started in 2019, is one of 55 in phase 3, and was the 268th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies in Fibromyalgia with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of fibromyalgia.

03

Conditions studied

  • Fibromyalgia

Keywords

  • Pain
  • Sleep
  • Fibromyalgia
  • FM
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient is male or female 18 to 65 years of age, inclusive.
  • The patient has a diagnosis of primary FM as defined by the 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria (American College of Rheumatology Preliminary Diagnostic Criteria)
  • The in-clinic 7-day recall NRS average daily pain intensity score at Screening Visit within protocol specified range.

Exclusion criteria

Exclusion Criteria:

  • History of or evidence for a diagnosis of borderline personality disorder (BPD).
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
503 participants (actual)

Study arms

  • Experimental
    TNX-102 SL Tablets, 5.6 mg

    1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.

    Drug: TNX-102 SL

  • Placebo comparator
    Placebo SL Tablet

    1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.

    Drug: Placebo SL Tablet

Interventions

  • Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.

    Also known as: Low dose cyclobenzaprine sublingual tablets

  • DrugPlacebo SL Tablet

    Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.

    Also known as: Placebo sublingual tablets

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores.

    Patients provide a daily numeric assessment of their average pain (24-hour recall), via an electronic diary, using an 11-point NRS. Scores range from 0 (no pain) to 10 (worst possible pain).

    Time frame: 14 weeks

Secondary outcomes

  1. Number of Patients With a Patient's Global Impression of Change (PGIC) Rating of "Very Much Improved" or "Much Improved"

    The PGIC is a fibromyalgia specific validated instrument on a scale of 1 to 7, where a score of 1 indicates the highest level of improvement and a score of 7 indicates a much worse outcome.

    Time frame: 14 weeks

  2. Change From Baseline to Week 14 in the Fibromyalgia Impact Questionnaire - Revised (FIQR) Symptoms Domain Score

    The FIQ-R is a validated questionnaire. Scores on the symptoms domain range from 0 to 100 where a higher score means worse outcome.

    Time frame: 14 weeks

  3. Change From Baseline to Week 14 in the FIQR Function Domain Score

    The FIQ-R is a validated questionnaire. Scores on the function domain range from 0 to 90 where a higher score means worse outcome.

    Time frame: 14 weeks

  4. Change From Baseline to Week 14 in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance

    The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40.

    Time frame: 14 weeks

  5. Change From Baseline to Week 14 in the PROMIS Score for Fatigue

    The PROMIS fatigue short form 8a consists of 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40.

    Time frame: 14 weeks

  6. Change From Baseline to Week 14 in the Weekly Average of the Daily Diary Assessment of Sleep Quality

    Patients provide a daily numeric assessment of their sleep quality for the previous night, via an electronic diary, using an 11-point NRS. Scores range from 0 (best possible sleep) to 10 (worst possible sleep).

    Time frame: 14 weeks

07

Results

Posted Aug 8, 2022
Limitations and caveats
Recruitment during COVID-19 pandemic

Participant flow

Participant flow — Overall Study
MilestoneTNX-102 SL Tablets, 5.6 mgPlacebo SL Tablet
Started248255
Completed204213
Not completed4442
Withdrew: Adverse event219
Withdrew: Lack of efficacy28
Withdrew: Physician decision01
Withdrew: Withdrawal by subject1211
Withdrew: Lost to follow-up49
Withdrew: Covid-19 related crisis33
Withdrew: Subject non-compliance11
Withdrew: Family emergency10

Outcome measures

PrimaryChange From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores.

Patients provide a daily numeric assessment of their average pain (24-hour recall), via an electronic diary, using an 11-point NRS. Scores range from 0 (no pain) to 10 (worst possible pain).

Time frame:
14 weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores.
score on a scaleTNX-102 SL Tablets, 5.6 mgPlacebo SL Tablet
Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores.-1.9 (-2.1 to -1.7)-1.5 (-1.7 to -1.3)
Statistical analysis
  • TNX-102 SL Tablets, 5.6 mg vs Placebo SL Tablet · Mixed Model Repeated Measures · p = 0.010 · Ls mean difference: -0.4 · 95% CI -0.7 to -0.1Treatment Difference = TNX-102 - Placebo
SecondaryNumber of Patients With a Patient's Global Impression of Change (PGIC) Rating of "Very Much Improved" or "Much Improved"

The PGIC is a fibromyalgia specific validated instrument on a scale of 1 to 7, where a score of 1 indicates the highest level of improvement and a score of 7 indicates a much worse outcome.

Time frame:
14 weeks
Reported as:
Count of participants · Participants
Number of Patients With a Patient's Global Impression of Change (PGIC) Rating of "Very Much Improved" or "Much Improved"
ParticipantsTNX-102 SL Tablets, 5.6 mgPlacebo SL Tablet
Number of Patients With a Patient's Global Impression of Change (PGIC) Rating of "Very Much Improved" or "Much Improved"9375
Statistical analysis
  • TNX-102 SL Tablets, 5.6 mg vs Placebo SL Tablet · Regression, Logistic · p = 0.058 · Odds ratio (or): 1.44 · 95% CI 0.99 to 2.10
SecondaryChange From Baseline to Week 14 in the Fibromyalgia Impact Questionnaire - Revised (FIQR) Symptoms Domain Score

The FIQ-R is a validated questionnaire. Scores on the symptoms domain range from 0 to 100 where a higher score means worse outcome.

Time frame:
14 weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 14 in the Fibromyalgia Impact Questionnaire - Revised (FIQR) Symptoms Domain Score
score on a scaleTNX-102 SL Tablets, 5.6 mgPlacebo SL Tablet
Change From Baseline to Week 14 in the Fibromyalgia Impact Questionnaire - Revised (FIQR) Symptoms Domain Score-18.4 (-20.8 to -16.0)-14.0 (-16.4 to -11.7)
Statistical analysis
  • TNX-102 SL Tablets, 5.6 mg vs Placebo SL Tablet · Mixed Model Repeated Measures · p = 0.007 · Ls mean difference: -4.3 · 95% CI -7.5 to -1.2Treatment Difference = TNX-102 - Placebo
SecondaryChange From Baseline to Week 14 in the FIQR Function Domain Score

The FIQ-R is a validated questionnaire. Scores on the function domain range from 0 to 90 where a higher score means worse outcome.

Time frame:
14 weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 14 in the FIQR Function Domain Score
score on a scaleTNX-102 SL Tablets, 5.6 mgPlacebo SL Tablet
Change From Baseline to Week 14 in the FIQR Function Domain Score-13.6 (-16.1 to -11.2)-9.3 (-11.7 to -6.8)
Statistical analysis
  • TNX-102 SL Tablets, 5.6 mg vs Placebo SL Tablet · Mixed Model Repeated Measures · p = 0.009 · Ls mean difference: -4.4 · 95% CI -7.7 to -1.1Treatment Difference = TNX-102 - Placebo
SecondaryChange From Baseline to Week 14 in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance

The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40.

Time frame:
14 weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 14 in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance
score on a scaleTNX-102 SL Tablets, 5.6 mgPlacebo SL Tablet
Change From Baseline to Week 14 in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance-9.5 (-10.7 to -8.2)-6.5 (-7.7 to -5.4)
Statistical analysis
  • TNX-102 SL Tablets, 5.6 mg vs Placebo SL Tablet · Mixed Model Repeated Measures · p = <0.001 · Ls mean difference: -2.9 · 95% CI -4.5 to -1.3Treatment Difference = TNX-102 - Placebo
SecondaryChange From Baseline to Week 14 in the PROMIS Score for Fatigue

The PROMIS fatigue short form 8a consists of 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40.

Time frame:
14 weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 14 in the PROMIS Score for Fatigue
score on a scaleTNX-102 SL Tablets, 5.6 mgPlacebo SL Tablet
Change From Baseline to Week 14 in the PROMIS Score for Fatigue-8.0 (-9.1 to -6.9)-6.2 (-7.4 to -5.0)
Statistical analysis
  • TNX-102 SL Tablets, 5.6 mg vs Placebo SL Tablet · Mixed Model Repeated Measures · p = 0.018 · Ls mean difference: -1.8 · 95% CI -3.3 to -0.3Treatment Difference = TNX-102 - Placebo
SecondaryChange From Baseline to Week 14 in the Weekly Average of the Daily Diary Assessment of Sleep Quality

Patients provide a daily numeric assessment of their sleep quality for the previous night, via an electronic diary, using an 11-point NRS. Scores range from 0 (best possible sleep) to 10 (worst possible sleep).

Time frame:
14 weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 14 in the Weekly Average of the Daily Diary Assessment of Sleep Quality
score on a scaleTNX-102 SL Tablets, 5.6 mgPlacebo SL Tablet
Change From Baseline to Week 14 in the Weekly Average of the Daily Diary Assessment of Sleep Quality-2.0 (-2.3 to -1.8)-1.5 (-1.7 to -1.2)
Statistical analysis
  • TNX-102 SL Tablets, 5.6 mg vs Placebo SL Tablet · Mixed Model Repeated Measures · p = <0.001 · Ls mean difference: -0.6 · 95% CI -0.9 to -0.3Treatment Difference = TNX-102 - Placebo

Adverse events

Collected over 14 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TNX-102 SL Tablets, 5.6 mg0/248 (0%)2/248 (0.8%)70/248 (28.2%)
Placebo SL Tablet0/255 (0%)5/255 (2%)3/255 (1.2%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventTNX-102 SL Tablets, 5.6 mgPlacebo SL Tablet
Spinal compression fractureInjury, poisoning and procedural complications1/2480/255
PneumoniaInfections and infestations1/2480/255
Thoracic vertebral fractureInjury, poisoning and procedural complications1/2480/255
Coeliac artery compression syndromeGastrointestinal disorders0/2481/255
Corona virus infectionInfections and infestations0/2481/255
Femoral neck fractureInjury, poisoning and procedural complications0/2481/255
HypotentionVascular disorders0/2481/255
ColitisGastrointestinal disorders0/2481/255
Femur fractureInjury, poisoning and procedural complications0/2481/255
Foot fractureInjury, poisoning and procedural complications0/2481/255
Most frequent other events
Most frequent other events
EventTNX-102 SL Tablets, 5.6 mgPlacebo SL Tablet
Hypoaesthesia oralGastrointestinal disorders43/2481/255
Paraesthesia oralGastrointestinal disorders14/2481/255
DysguesiaNervous system disorders13/2481/255

Baseline characteristics

Age, Continuous
Age, Continuous(years)TNX-102 SL Tablets, 5.6 mgPlacebo SL TabletTotal
Mean50.0 ± 9.4049.3 ± 10.1649.6 ± 9.79
Sex: Female, Male
Sex: Female, Male(Participants)TNX-102 SL Tablets, 5.6 mgPlacebo SL TabletTotal
Female232247479
Male16824
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TNX-102 SL Tablets, 5.6 mgPlacebo SL TabletTotal
American Indian or Alaska Native123
Asian257
Native Hawaiian or Other Pacific Islander011
Black or African American192039
White222216438
More than one race3912
Unknown or Not Reported123
Region of Enrollment
Region of Enrollment(participants)TNX-102 SL Tablets, 5.6 mgPlacebo SL TabletTotal
United States248255503
08

Study locations

39 sites
  • Tonix Clinical Site
    Birmingham, Alabama 35216, United States
  • Tonix Clinical Site
    Phoenix, Arizona 85016, United States
  • Tonix Clinical Site
    Oceanside, California 92056, United States
  • Tonix Clinical Site
    Sacramento, California 95831, United States
  • Tonix Clinical Site
    San Diego, California 92103, United States
  • Tonix Clinical Site
    Temecula, California 32591, United States
  • Tonix Clinical Site
    Cromwell, Connecticut 06416, United States
  • Tonix Clinical Site
    Fort Myers, Florida 33912, United States
  • Tonix Clinical Site
    Jacksonville, Florida 32256, United States
  • Tonix Clinical Site
    North Miami, Florida 33161, United States
  • Tonix Clinical Site
    Ocala, Florida 34470, United States
  • Tonix Clinical Site
    Orlando, Florida 32801, United States
  • Tonix Clinical Site
    Atlanta, Georgia 30341, United States
  • Tonix Clinical Site
    Evansville, Indiana 47714, United States
  • Tonix Clinical Site
    West Des Moines, Iowa 50265, United States
  • Tonix Clinical Site
    Prairie Village, Kansas 66208, United States
  • Tonix Clinical Site
    New Orleans, Louisiana 70115, United States
  • Tonix Clinical Site
    Boston, Massachusetts 02131, United States
  • Tonix Clinical Site
    North Dartmouth, Massachusetts 02747, United States
  • Tonix Clinical Site
    Las Vegas, Nevada 89102, United States
  • Tonix Clinical Site
    Williamsville, New York 14221, United States
  • Tonix Clinical Site
    High Point, North Carolina 27262, United States
  • Tonix Clinical Site
    Raleigh, North Carolina 27612, United States
  • Tonix Clinical Site
    Fargo, North Dakota 58104, United States
  • Tonix Clinical Site
    Cincinnati, Ohio 45219, United States
  • Tonix Clinical Site
    Dayton, Ohio 45417, United States
  • Tonix Clinical Site
    North Canton, Ohio 44720, United States
  • Tonix Clinical Site
    Oklahoma City, Oklahoma 73112, United States
  • Tonix Clinical Site
    Tulsa, Oklahoma 74133, United States
  • Tonix Clinical Site
    Portland, Oregon 97210, United States
  • Tonix Clinical Site
    Allentown, Pennsylvania 18104, United States
  • Tonix Clinical Site
    Warwick, Rhode Island 02886, United States
  • Tonix Clinical Site
    Chattanooga, Tennessee 37421, United States
  • Tonix Clinical Site
    Memphis, Tennessee 38119, United States
  • Tonix Clinical Site
    Austin, Texas 78737, United States
  • Tonix Clinical Site
    Dallas, Texas 75231, United States
  • Tonix Clinical Site
    Salt Lake City, Utah 84102, United States
  • Tonix Clinical Site
    Charlottesville, Virginia 22911, United States
  • Tonix Clinical Site
    Kenosha, Wisconsin 53144, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Oct 2020, 10 months.

Results were first posted in Aug 2022, 1 year 9 months after primary completion.

Of 17 phase 3 interventional studies under Fibromyalgia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2019
First posted
Nov 21, 2019
StartActual
Dec 9, 2019
Primary completionActual
Oct 29, 2020
CompletionActual
Oct 29, 2020
Results first posted
Aug 8, 2022
Last update
Aug 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04172831
Responsible party
Sponsor
First posted
Nov 21, 2019
Start date
Dec 9, 2019
Primary completion
Oct 29, 2020
Completion
Oct 29, 2020
Results posted
Aug 8, 2022
Last update
Aug 8, 2022

Study contacts

Gregory Sullivan, MD
study director · Tonix Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclobenzaprine

Start the discussion